openPR Logo
Press release

Global Cancer Nanomedicine Market & Cancer Nanomedicine Clinical Trials Outlook 2022

07-07-2017 08:54 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Cancer Nanomedicine Market & Cancer Nanomedicine

Over the past several years, many innovative and revolutionary techniques have been developed in order to treat cancer. These techniques range from basic surgical removal to X-ray irradiation to system wide flooding with anticancer agents. However, each of these approaches has its own series of undesirable side effects that are both dangerous and damaging to the overall health of the patient. On the contrary, very recent breakthroughs in nanomedicine have managed to change all that. Now at last there is hope for a cure that is effective and can be made it safe.

Indeed, there is still plenty of work to be done, some very promising new nanomedicine treatment methods are in the works. Nanomedicine treatments can be used in both the preventive and in the therapeutic approaches to deal with cancer. With better knowledge researchers are able to engineer more sophisticated nanodevices and to equip them with effective targeting techniques for biomolecules; will gain the ability to treat various kinds of cancer more and more effectively.

The future of cancer nanotechnology lies on a multifunctional nanoplatform that combines both therapeutic components and multimodality imaging. The ultimate goal is that multifunctional nanomedicine works as efficient, targeted in vivo drug delivery without systemic toxicity, and the dose delivered as well as the therapeutic efficacy can be accurately measured noninvasively with time.

Diagnosis and therapy combined in one system is the current advanced biomedical tool referred to as theragnostics. The primary goal of theragnostics is to selectively target the disease confined to tissue/cell in order to increase diagnostic and therapeutic selectivity that makes the treatment shorter, safer, effective and inexpensive. Biocompatible/biodegradable nanocarriers are currently under development in oncological theragnostics that would enable precise diagnosis and therapy.

For Report Sample Contact: or +91-11-47067990

Download Report:

Report Table of Contents

Cancer Nanomedicine: An Optimistic Avenue
1.1 Introduction
1.2 Emergence of Nanomedicines

Prerequisite of Nanomedicines
2.1 Conventional Cancer Treating Approaches
2.2 Nanomedicines: Overcoming the Hurdles

Diversification of Nanomedicines
3.1 Classification on Basis of Constituents
3.1.1 Inorganic Nanoparticles
3.1.2 Organic Nanoparticles
3.2 Classification on Basis of Applicability
3.2.1 Nanomedicine as Diagnostic Agents
3.2.2 Nanomedicine as Therapeutic Agents
3.2.3 Nanomedicine as Drug Delivery Agents
3.3 Classification on Basis of Dimensions

Mechanism of Action of Nanomedicine
4.1 Targeting Tumor Cells
4.1.1 Passive Targeting
4.1.2 Active Targeting
4.2 Nanocarrier - Drug Complex
4.2.1 Liposomes
4.2.2 Dendrimers
4.2.3 Micelles
4.2.4 Inorganic Nanocarriers
4.3 Drug Release Systems

Nanomedicine Engineering: Design and Strategy
5.1 Organic Nanoparticles as Nanomedicines
5.1.1 Polymeric Nanoparticle
5.1.2 Lipid Organic Nanoparticles
5.2 Inorganic Nanoparticles as Nanomedicines
5.2.1 Synthesis of Gold Nanoparticle

Cancer Nanomedicine as Diagnostic Tool
6.1 Detection of Cancer Biomarkers
6.1.1 Detection of Circulating Tumor Cell
6.2 Diagnostic Device and Nanoprobes
6.2.1 Biosensors
6.2.2 Microarrays
6.3 Quantum Dots for Early Cancer Detection
6.3.1 Detection of primary Cancers
6.3.2 Quantum Dots for Tumor Imaging

Cancer Therapeutics with Nanomedicines
7.1 Nanomedicine as Therapeutic Agents
7.1.1 Photodynamic Therapy
7.1.2 Photo Thermal Therapy
7.2 Nanomedicines as Prophylactic and Therapeutic Approach
7.2.1 Cancer Cell Destruction
7.3 Nanomedicine in Breast Cancer
7.4 Nanomedicine in Pancreatic Cancer
7.5 Nanomedicine in Brain Cancer
7.6 Nanomedicine in Lung Cancer

Cancer Imaging with Nanomedicine
8.1 Positron Emission Tomography
8.1.1 Applications in various Cancers
8.2 Single Photon Emitted Tomography
8.2.1 Computed Tomography
8.3 Magnetic Resonance Imaging (MRI)
8.3.1 Optical Imaging

Drug Delivery with Nanomedicines
9.1 Nanocarrier and Chemotherapy
9.1.1 Peptide Nanomedicine- An Example of Nanocarrier Chemotherapy
9.2 Nanomedicine Endocytosis and Intracellular Mechanisms
9.3 Factors Affecting Drug Delivery

Global Cancer Nanomedicine Market Overview
10.1 Current Market Scenario
10.2 Global Cancer Nanomedicine Clinical Pipeline Overview

Global Nanomedicine Market Dynamics
11.1 Encouraging Market Aspects
11.2 Commercialization Challenges

Global Cancer Nanomedicine Future Prospect

Global Cancer Nanomedicine Clinical Pipeline by Company, Indication and Phase
13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-III

Marketed Cancer Nanomedicine Clinical Insight by Company, Indication and Phase
14.1 Caelyx and Doxil
14.2 Albumin-Bound Paclitaxel (Abraxane and Coraxane)
14.3 Nilotinib (Tasigna)
14.4 Paclitaxel Polymeric Micelle Formulation (Cynviloq and Genexol-PM)
14.5 Paclitaxel Liposomal
14.6 Vincristine Liposomal (Marqibo)
14.7 Rexin-G
14.8 Paclitaxel Nanoparticle (Nanoxel)

Competitive Landscape
15.1 Abraxis BioScience
15.2 Access Pharmaceuticals
15.3 Alnylam Pharmaceuticals
15.4 Amgen
15.5 Arrowhead Research
15.6 BIND Therapeutics
15.7 Cadila Healthcare
15.8 Celegen Corporation
15.9 Celsion Corporation
15.10 Genzyme Corporation
15.11 Merck
15.12 NanoCarrier
15.13 Nippon Kayaku
15.14 Nanobiotix
15.15 Novavax
15.16 Pfizer
15.17 Roche
15.18 Samyang
15.19 Sanofi
15.20 Takeda Pharmaceutical

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Cancer Nanomedicine Market & Cancer Nanomedicine Clinical Trials Outlook 2022 here

News-ID: 613348 • Views: 375

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases